Depomed (NASDAQ DEPO) shares were hammered on Tuesday after the
company announced that it's drug for neuropathic pain did not reach its
It does not appear that DEPO has any near term cash or liquidity
issues. Therefore the nearly 60% drop in share price may provide
investors with a positive risk versus reward opportunity as the company
continues to explore other drugs in it's pipeline.